Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

Articles published in
J Infect Dis
    August 2022
  1. GREBE E, Yu EA, Bravo MD, Welte A, et al
    COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
    J Infect Dis. 2022 Aug 3. pii: 6654836. doi: 10.1093.
    >> Share

    July 2022
  2. VIVALDI G, Jolliffe DA, Faustini S, Shields AM, et al
    Correlation between post-vaccination anti-Spike antibody titres and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study.
    J Infect Dis. 2022 Jul 30. pii: 6652292. doi: 10.1093.
    >> Share

  3. LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
    Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
    J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
    >> Share

  4. KNOLL MD, Bennett JC, Yang Y, Quesada MG, et al
    Challenges inferring pneumococcal conjugate vaccine impact from bacterial surveillance data.
    J Infect Dis. 2022 Jul 28. pii: 6650942. doi: 10.1093.
    >> Share

  5. CHU WM, Lee YH, Cheng-Chung Wei J, Lee YH, et al
    Comment on Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
    J Infect Dis. 2022 Jul 26. pii: 6649924. doi: 10.1093.
    >> Share

  6. CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
    Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
    J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
    >> Share

  7. MAHANT A, Guerguis S, Blevins TP, Cheshenko N, et al
    Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    J Infect Dis. 2022 Jul 14. pii: 6644507. doi: 10.1093.
    >> Share

  8. BRADFUTE S, Mertz G
    Immune responses to herpes simplex virus infection: implications for vaccine development.
    J Infect Dis. 2022 Jul 8. pii: 6633820. doi: 10.1093.
    >> Share

  9. WAGNER AL, Sanchez N, Kubale J, Kuan G, et al
    Single dose vaccination among infants and toddlers provides modest protection against influenza illness which wanes after 5 months.
    J Infect Dis. 2022 Jul 7. pii: 6633354. doi: 10.1093.
    >> Share

  10. COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
    Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
    J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
    >> Share

  11. ASSAWAKOSRI S, Suntronwong N, Yorsaeng R, Kanokudom S, et al
    Breakthrough infection by SARS-CoV-2 Delta and Omicron variants elicited immune response comparable to mRNA booster vaccination.
    J Infect Dis. 2022 Jul 5. pii: 6631219. doi: 10.1093.
    >> Share

  12. REN Z, Sun R, Cui G, Wang H, et al
    Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants.
    J Infect Dis. 2022 Jul 5. pii: 6631218. doi: 10.1093.
    >> Share

  13. NYOMBAYIRE J, Ingabire R, Magod B, Mazzei A, et al
    Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
    J Infect Dis. 2022 Jul 1. pii: 6625827. doi: 10.1093.
    >> Share

    June 2022
  14. DEMASO CR, Karwal L, Zahralban-Steele M, Dominguez D, et al
    Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue Vaccine.
    J Infect Dis. 2022 Jun 30. pii: 6623496. doi: 10.1093.
    >> Share

  15. VENCALEK O, Beran J, Furst T, Kratka Z, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Jun 28. pii: 6619238. doi: 10.1093.
    >> Share

  16. LLIBRE JM, Revollo B, Aguilar S, Calomarde-Gomez C, et al
    Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
    J Infect Dis. 2022 Jun 28. pii: 6619237. doi: 10.1093.
    >> Share

  17. MOY JN, Anderson M, Shen X, Fu J, et al
    Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 Vaccine in Infection-Naive and Previously-Infected Individuals.
    J Infect Dis. 2022 Jun 27. pii: 6618640. doi: 10.1093.
    >> Share

  18. AMJADI MF, Adyniec RR, Gupta S, Bashar SJ, et al
    Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination.
    J Infect Dis. 2022 Jun 27. pii: 6618636. doi: 10.1093.
    >> Share

  19. MOODIE Z, Dintwe O, Sawant S, Grove D, et al
    Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.
    J Infect Dis. 2022 Jun 27. pii: 6618597. doi: 10.1093.
    >> Share

  20. STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
    Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
    J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
    >> Share

  21. CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
    Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
    J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
    >> Share

  22. VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
    Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
    J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
    >> Share

  23. GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
    High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
    J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
    >> Share

  24. LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
    Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
    J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
    >> Share

  25. DONATO CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, et al
    Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.
    J Infect Dis. 2022;225:2116-2126.
    >> Share

  26. SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
    Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
    J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
    >> Share

  27. JACOBSON JM
    Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
    J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
    >> Share

  28. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
    J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
    >> Share

  29. STORCH GA
    Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
    J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
    >> Share

    May 2022
  30. ROSTAD CA, Chen X, Sun HY, Hussaini L, et al
    Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination.
    J Infect Dis. 2022 May 26. pii: 6593309. doi: 10.1093.
    >> Share

  31. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    >> Share

  32. NALIN D
    Cholera control requires reducing mortality along with vaccination programs.
    J Infect Dis. 2022 May 18. pii: 6588066. doi: 10.1093.
    >> Share

  33. AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
    Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
    J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.
    >> Share

  34. AZIZ AB, Verma H, Jeyaseelan V, Md Y, et al
    One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomized clinical trial in Bangladesh.
    J Infect Dis. 2022 May 16. pii: 6586252. doi: 10.1093.
    >> Share

  35. FAUSTHER-BOVENDO H, Qiu X, Babuadze GG, Azizi H, et al
    Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
    J Infect Dis. 2022;225:1852-1855.
    >> Share

  36. BABER J, Arya M, Moodley Y, Jaques A, et al
    A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
    >> Share

  37. MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
    Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
    J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
    >> Share

  38. EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
    Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
    J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
    >> Share

  39. MUHR LSA, Eklund C, Lagheden C, Eriksson T, et al
    Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
    J Infect Dis. 2022 May 10. pii: 6582940. doi: 10.1093.
    >> Share

  40. LIU B, Stepien S, Pye V, Law C, et al
    High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
    J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
    >> Share

  41. KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
    Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
    J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
    >> Share

  42. MITSI E, McLenaghan D, Wolf AS, Jones S, et al
    Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
    J Infect Dis. 2022;225:1626-1631.
    >> Share

  43. SIRIVICHAYAKUL C, Barranco-Santana EA, Rivera IE, Kilbury J, et al
    Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    J Infect Dis. 2022;225:1513-1520.
    >> Share

    April 2022
  44. SMID M, Berec L, Pribylova L, Majek O, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Apr 28. pii: 6575414. doi: 10.1093.
    >> Share

  45. TJAN LH, Furukawa K, Kurahashi Y, Sutandhio S, et al
    As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
    J Infect Dis. 2022 Apr 28. pii: 6575227. doi: 10.1093.
    >> Share

  46. BAJEMA KL, Gierke R, Farley MM, Schaffner W, et al
    Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States.
    J Infect Dis. 2022 Apr 28. pii: 6575225. doi: 10.1093.
    >> Share

  47. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Puenpa J, et al
    Omicron BA.1, BA.2 and COVID-19 booster vaccination.
    J Infect Dis. 2022 Apr 27. pii: 6575160. doi: 10.1093.
    >> Share

  48. LIN DY, Zeng D, Gu Y, Krause PR, et al
    Reliably Assessing Duration of Protection for COVID-19 Vaccines.
    J Infect Dis. 2022 Apr 21. pii: 6571630. doi: 10.1093.
    >> Share

  49. BROKAW A, Nguyen S, Quach P, Orvis A, et al
    A recombinant alpha-like protein subunit vaccine (GBS-NN) provides protection in murine models of Group B Streptococcus infection.
    J Infect Dis. 2022 Apr 16. pii: 6569354. doi: 10.1093.
    >> Share

  50. ZHU KL, Gao HX, Yao L, Rong J, et al
    Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron.
    J Infect Dis. 2022 Apr 16. pii: 6569353. doi: 10.1093.
    >> Share

  51. LE GARS M, Sadoff J, Struyf F, Heerwegh D, et al
    Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
    J Infect Dis. 2022 Apr 16. pii: 6569363. doi: 10.1093.
    >> Share

  52. BOLOTIN S, Osman S, Hughes SL, Ariyarajah A, et al
    In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022 Apr 13. pii: 6568034. doi: 10.1093.
    >> Share

  53. PERMAR SR, Kaur A, Fruh K
    De-risking human cytomegalovirus vaccine clinical development in relevant preclinical models.
    J Infect Dis. 2022 Apr 13. pii: 6567687. doi: 10.1093.
    >> Share

  54. LI J, Wellnitz S, Chi XS, Yue Y, et al
    Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses.
    J Infect Dis. 2022 Apr 12. pii: 6567520. doi: 10.1093.
    >> Share

  55. KWON JH, Tenforde MW, Gaglani M, Talbot HK, et al
    mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients.
    J Infect Dis. 2022 Apr 6. pii: 6564370. doi: 10.1093.
    >> Share

  56. XIONG W, Tsang TK, Perera RAPM, Leung NHL, et al
    Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children.
    J Infect Dis. 2022 Apr 5. pii: 6563665. doi: 10.1093.
    >> Share

  57. CARR OJJ, Vilivong K, Bounvilay L, Dunne EM, et al
    Nasopharyngeal Pneumococcal Colonization Density Is Associated With Severe Pneumonia in Young Children in the Lao People's Democratic Republic.
    J Infect Dis. 2022;225:1266-1273.
    >> Share

    March 2022
  58. MARON JS, Conroy M, Naranbai V, Samarakoon U, et al
    Differential SARS-CoV-2 Antibody Profiles after Allergic Reactions to mRNA COVID-19 Vaccine.
    J Infect Dis. 2022 Mar 23. pii: 6553054. doi: 10.1093.
    >> Share

  59. RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
    Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
    J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
    >> Share

  60. LEWNARD JA, Bruxvoort KJ, Hong VX, Grant LR, et al
    Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study.
    J Infect Dis. 2022 Mar 22. pii: 6552253. doi: 10.1093.
    >> Share

  61. LI X, Bilcke J, Vazquez Fernandez L, Bont L, et al
    Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    J Infect Dis. 2022 Mar 16. pii: 6549175. doi: 10.1093.
    >> Share

  62. ROHRIG A, Eyal N
    The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    J Infect Dis. 2022;225:934-937.
    >> Share

  63. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Auphimai C, et al
    Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    J Infect Dis. 2022 Mar 10. pii: 6546425. doi: 10.1093.
    >> Share

  64. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    >> Share

  65. SANTONJA I, Stiasny K, Essl A, Heinz FX, et al
    Tick-borne encephalitis in vaccinated patients: a retrospective case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018.
    J Infect Dis. 2022 Mar 2. pii: 6541329. doi: 10.1093.
    >> Share

    February 2022
  66. MORITZKY SA, Richards KA, Glover MA, Krammer F, et al
    The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history.
    J Infect Dis. 2022 Feb 24. pii: 6535476. doi: 10.1093.
    >> Share

  67. BELSHE RB, Blevins TP, Yu Y, Nethington AE, et al
    Neutralizing Antibody Kinetics and Immune Protection Against HSV-1 Genital Disease in Vaccinated Women.
    J Infect Dis. 2022 Feb 24. pii: 6535411. doi: 10.1093.
    >> Share

  68. LENTSCHER AJ, McAllister N, Griswold KA, Martin JL, et al
    Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challenge.
    J Infect Dis. 2022 Feb 23. pii: 6535121. doi: 10.1093.
    >> Share

  69. BURNETT E, Parashar UD, Winn A, Tate JE, et al
    Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021.
    J Infect Dis. 2022 Feb 20. pii: 6532606. doi: 10.1093.
    >> Share

  70. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Grill DE, et al
    Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination.
    J Infect Dis. 2022 Feb 8. pii: 6524526. doi: 10.1093.
    >> Share

  71. KIM N, Shin S, Minn D, Park S, et al
    SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study.
    J Infect Dis. 2022 Feb 1. pii: 6519374. doi: 10.1093.
    >> Share

  72. RYAN KA, Schewe KE, Crowe J, Fotheringham SA, et al
    Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.
    J Infect Dis. 2022;225:404-412.
    >> Share

    January 2022
  73. SPENGLER JR, Kainulainen MH, Welch SR, Coleman-McCray JAD, et al
    Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.
    J Infect Dis. 2022 Jan 31. pii: 6517689. doi: 10.1093.
    >> Share

  74. SKOWRONSKI DM, Setayeshgar S, Zou M, Prystajecky N, et al
    Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada.
    J Infect Dis. 2022 Jan 27. pii: 6515934. doi: 10.1093.
    >> Share

  75. KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
    J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
    >> Share

  76. GUAN M, Johannesen E, Tang CY, Hsu AL, et al
    Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination.
    J Infect Dis. 2022 Jan 13. pii: 6506263. doi: 10.1093.
    >> Share

  77. KRISTENSEN JH, Hasselbalch RB, Pries-Heje M, Nielsen PB, et al
    Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers.
    J Infect Dis. 2022 Jan 5. pii: 6497955. doi: 10.1093.
    >> Share

  78. CHU VT, Simon E, Lu X, Rockwell P, et al
    Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019.
    J Infect Dis. 2022;225:55-64.
    >> Share

    December 2021
  79. LEWIS LA, Gulati S, Zelek WM, Morgan BP, et al
    Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement.
    J Infect Dis. 2021 Dec 31. pii: 6491069. doi: 10.1093.
    >> Share

  80. LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
    Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
    J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
    >> Share

  81. BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
    Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
    J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
    >> Share

  82. LIU J, Huang B, Li G, Chang X, et al
    Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
    J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
    >> Share

  83. ABARA WE, Gee J, Delorey M, Tun Y, et al
    Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.
    J Infect Dis. 2021 Dec 27. pii: 6484617. doi: 10.1093.
    >> Share

  84. KIM SS, Naioti EA, Halasa NB, Stewart LS, et al
    Vaccine Effectiveness against Influenza Hospitalization and Emergency Department Visits in Two A(H3N2) Dominant Influenza Seasons among Children <18 Years Old, New Vaccine Surveillance Network 2016-17 and 2017-18.
    J Infect Dis. 2021 Dec 24. pii: 6482612. doi: 10.1093.
    >> Share

  85. PHIJFFER EWEM, Bont LJ
    Are we ready for maternal RSV vaccination?
    J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
    >> Share

  86. LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
    Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
    J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
    >> Share

  87. WALSH EE, Falsey AR, Scott DA, Gurtman A, et al
    A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472747. doi: 10.1093.
    >> Share

  88. FALSEY AR, Walsh EE, Scott DA, Gurtman A, et al
    Phase 1/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472733. doi: 10.1093.
    >> Share

  89. IYER AS, Harris JB
    Correlates of Protection for Cholera.
    J Infect Dis. 2021;224.
    >> Share

  90. SAHA GK, Ganguly NK
    Spread and Endemicity of Cholera in India: Factors Beyond the Numbers.
    J Infect Dis. 2021;224.
    >> Share

  91. CHAO DL
    Mathematical Modeling of Endemic Cholera Transmission.
    J Infect Dis. 2021;224.
    >> Share

  92. SACK DA, Debes AK, Ateudjieu J, Bwire G, et al
    Contrasting Epidemiology of Cholera in Bangladesh and Africa.
    J Infect Dis. 2021;224.
    >> Share

  93. FLECKENSTEIN JM, Sheikh A
    Emerging Themes in the Molecular Pathogenesis of Enterotoxigenic Escherichia coli.
    J Infect Dis. 2021;224.
    >> Share

  94. BRUNHAM RC
    Problems with Understanding Chlamydia trachomatis Immunology.
    J Infect Dis. 2021 Dec 17. pii: 6469012. doi: 10.1093.
    >> Share

  95. HASTIE A, Catteau G, Enemuo A, Mrkvan T, et al
    Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    J Infect Dis. 2021;224:2025-2034.
    >> Share

  96. HUI BB, Padeniya TN, Rebuli N, Gray RT, et al
    A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men.
    J Infect Dis. 2021 Dec 11. pii: 6459455. doi: 10.1093.
    >> Share

  97. CHRISTENSEN H, Vickerman P
    Gonococcal vaccines for controlling Neisseria gonorrhoeae in men who have sex with men: a promising game-changer.
    J Infect Dis. 2021 Dec 11. pii: 6459454. doi: 10.1093.
    >> Share

  98. BROCKMAN MA, Mwimanzi F, Lapointe HR, Sang Y, et al
    Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
    J Infect Dis. 2021 Dec 9. pii: 6458430. doi: 10.1093.
    >> Share

  99. NARANBHAI V, Garcia-Beltran WF, Chang CC, Mairena CB, et al
    Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
    J Infect Dis. 2021 Dec 9. pii: 6458467. doi: 10.1093.
    >> Share

    November 2021
  100. GILBOA M, Mandelboim M, Indenbaum V, Lustig Y, et al
    Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
    J Infect Dis. 2021 Nov 29. pii: 6446235. doi: 10.1093.
    >> Share

  101. JOHNSON MJ, Liu C, Ghosh D, Lang N, et al
    Cell-Mediated Immune Responses After Administration Of The Live Or The Recombinant Zoster Vaccine: Five-Year Persistence.
    J Infect Dis. 2021 Nov 27. pii: 6444689. doi: 10.1093.
    >> Share

  102. KIM JY, Lim SY, Park S, Kwon JS, et al
    Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period.
    J Infect Dis. 2021 Nov 25. pii: 6440288. doi: 10.1093.
    >> Share

  103. RYCKMAN T, Karthikeyan AS, Kumar D, Cao Y, et al
    Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
    J Infect Dis. 2021;224.
    >> Share

  104. KUMAR S, Ghosh RS, Iyer H, Ray A, et al
    Typhoid in India: An Age-old Problem With an Existing Solution.
    J Infect Dis. 2021;224.
    >> Share

  105. CAO Y, Karthikeyan AS, Ramanujam K, Raju R, et al
    Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data.
    J Infect Dis. 2021;224.
    >> Share

  106. SINHA B, Rongsen-Chandola T, Goyal N, Arya A, et al
    Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier.
    J Infect Dis. 2021;224.
    >> Share

  107. MOHAN VR, Srinivasan M, Sinha B, Shrivastava A, et al
    Geographically Weighted Regression Modeling of Spatial Clustering and Determinants of Focal Typhoid Fever Incidence.
    J Infect Dis. 2021;224.
    >> Share

  108. AMBROSINO D, Han HH, Hu B, Liang J, et al
    Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    J Infect Dis. 2021 Nov 19. pii: 6431853. doi: 10.1093.
    >> Share

  109. FULDA ES, Fitch KV, Overton ET, Zanni MV, et al
    COVID-19 Vaccination Rates in a Global HIV Cohort.
    J Infect Dis. 2021 Nov 18. pii: 6431673. doi: 10.1093.
    >> Share

  110. COLLIER AY, Yu J, Mcmahan K, Liu J, et al
    COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.
    J Infect Dis. 2021 Nov 18. pii: 6430790. doi: 10.1093.
    >> Share

  111. ALAM MM, Ikram A, Mahmood N, Sharif S, et al
    Antigenic structure of wild poliovirus type 1 strains endemic in Pakistan is highly conserved and completely neutralized by Sabin's Oral Polio Vaccine.
    J Infect Dis. 2021 Nov 17. pii: 6430438. doi: 10.1093.
    >> Share

  112. DUARTE G, Muresan P, Ward S, Laimon L, et al
    Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.
    J Infect Dis. 2021 Nov 16. pii: 6429421. doi: 10.1093.
    >> Share

  113. BIERLE DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, et al
    Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    J Infect Dis. 2021 Nov 16. pii: 6429422. doi: 10.1093.
    >> Share

  114. JOHNSON S, Martinez CI, Tedjakusuma SN, Peinovich N, et al
    Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.
    J Infect Dis. 2021 Nov 10. pii: 6425228. doi: 10.1093.
    >> Share

  115. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    >> Share

  116. FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
    SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
    J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
    >> Share

  117. SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
    Effectiveness of a third dose of BNT162b2 mRNA vaccine.
    J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
    >> Share

    October 2021
  118. MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
    Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
    J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.
    >> Share

  119. CHAKRABORTY D, Kanungo S, Nandy RK, Deb AK, et al
    Challenges for Programmatic Implementation of Oral Cholera Vaccine in India.
    J Infect Dis. 2021 Oct 20. pii: 6404482. doi: 10.1093.
    >> Share

  120. CALLEGARO A, Burny W, Herve C, Kim JH, et al
    Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine.
    J Infect Dis. 2021 Oct 18. pii: 6400271. doi: 10.1093.
    >> Share

  121. WITHANAGE K, De Coster I, Cools N, Viviani S, et al
    Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results.
    J Infect Dis. 2021 Oct 15. pii: 6398205. doi: 10.1093.
    >> Share

  122. PRENTICE S, Dockrell HM
    BCG Specific and Nonspecific Effects: Different Questions, Similar Challenges.
    J Infect Dis. 2021;224:1105-1108.
    >> Share

  123. WILLIAMS FB, Kader A, Colgate ER, Dickson DM, et al
    Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh.
    J Infect Dis. 2021;224:1147-1151.
    >> Share

  124. DAGNEW AF, Klein NP, Herve C, Kalema G, et al
    The Adjuvanted Recombinant Zoster Vaccine in Adults Aged >/=65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    J Infect Dis. 2021;224:1139-1146.
    >> Share

  125. PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
    Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
    >> Share

  126. DILLER JR, Carter MH, Kanai Y, Sanchez SV, et al
    Monoreassortant rotaviruses of multiple G types are differentially neutralized by sera from infants vaccinated with ROTARIX(R) and RotaTeq(R).
    J Infect Dis. 2021 Oct 10. pii: 6386353. doi: 10.1093.
    >> Share

  127. DODD RY, Notari EP, Brodsky JP, Foster GA, et al
    Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.
    J Infect Dis. 2021 Oct 9. pii: 6385747. doi: 10.1093.
    >> Share

  128. LU Y, Jiao Y, Graham DJ, Wu Y, et al
    Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.
    J Infect Dis. 2021 Oct 7. pii: 6383455. doi: 10.1093.
    >> Share

  129. GAST C, Bandyopadhyay AS, Saez-Llorens X, De Leon T, et al
    Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials.
    J Infect Dis. 2021 Oct 5. pii: 6381642. doi: 10.1093.
    >> Share

  130. GERSHON AA, Gershon MD
    Widespread use of varicella vaccine does not reduce immunity to zoster of others.
    J Infect Dis. 2021 Oct 5. pii: 6381628. doi: 10.1093.
    >> Share

  131. CARRYN S, Cheuvart B, Povey M, Dagnew AF, et al
    No consistent evidence of decreased exposure to varicella-zoster virus among older adults in countries with universal varicella vaccination.
    J Infect Dis. 2021 Oct 5. pii: 6381619. doi: 10.1093.
    >> Share

    September 2021
  132. GLASS RI, Tate JE, Jiang B, Parashar U, et al
    The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
    J Infect Dis. 2021;224.
    >> Share

  133. MARKOWITZ LE, Schiller JT
    Human Papillomavirus Vaccines.
    J Infect Dis. 2021;224.
    >> Share

  134. GERSHON AA, Gershon MD, Shapiro ED
    Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
    J Infect Dis. 2021;224.
    >> Share

  135. BECKER T, Elbahesh H, Reperant LA, Rimmelzwaan GF, et al
    Influenza Vaccines: Successes and Continuing Challenges.
    J Infect Dis. 2021;224.
    >> Share

  136. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    >> Share

  137. RODGERS GL, Whitney CG, Klugman KP
    Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe.
    J Infect Dis. 2021;224.
    >> Share

  138. HARBECKE R, Cohen JI, Oxman MN
    Herpes Zoster Vaccines.
    J Infect Dis. 2021;224.
    >> Share

  139. GILSDORF JR
    Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease.
    J Infect Dis. 2021;224.
    >> Share

  140. BREMAN JG
    Smallpox.
    J Infect Dis. 2021;224.
    >> Share

  141. MODLIN JF, Bandyopadhyay AS, Sutter R
    Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    J Infect Dis. 2021;224.
    >> Share

  142. PLOTKIN SA
    Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
    J Infect Dis. 2021;224.
    >> Share

  143. DECKER MD, Edwards KM
    Pertussis (Whooping Cough).
    J Infect Dis. 2021;224.
    >> Share

  144. GASTANADUY PA, Goodson JL, Panagiotakopoulos L, Rota PA, et al
    Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination.
    J Infect Dis. 2021;224.
    >> Share

  145. MACLENNAN CA, Talaat KR, Kaminski RW, Cohen D, et al
    Critical needs in advancing Shigella vaccines for global health.
    J Infect Dis. 2021 Sep 24. pii: 6374897. doi: 10.1093.
    >> Share

  146. OKADA K, Miyazaki C, Kino Y, Ozaki T, et al
    Corrigendum to: Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).
    J Infect Dis. 2021 Sep 22. pii: 6374023. doi: 10.1093.
    >> Share

  147. SVENNERHOLM AM, Lundgren A, Leach S, Akhtar M, et al
    Mucosal immune responses against an oral ETEC vaccine evaluated in clinical trials.
    J Infect Dis. 2021 Sep 22. pii: 6373960. doi: 10.1093.
    >> Share

  148. BHUIYAN TR, Islam T, Qadri F
    Life Course Approach to Vaccination in Bangladesh for meeting the SDG health and health related goals - a commentary.
    J Infect Dis. 2021 Sep 22. pii: 6373867. doi: 10.1093.
    >> Share

  149. KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
    Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
    J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
    >> Share

  150. GAO H, Lau EHY, Cowling BJ
    Waning immunity after receipt of Pertussis, Diphtheria, Tetanus and Polio-related vaccines: a systematic review and meta-analysis.
    J Infect Dis. 2021 Sep 20. pii: 6372879. doi: 10.1093.
    >> Share

  151. HEO JY, Seo YB, Choi WS, Kim EJ, et al
    Effectiveness of Pneumococcal Vaccination Against Hospitalized Pneumococcal Pneumonia in Older Adults: A Prospective, Test-Negative Study.
    J Infect Dis. 2021 Sep 19. pii: 6372439. doi: 10.1093.
    >> Share

  152. FERREIRA IATM, Kemp SA, Datir R, Saito A, et al
    SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
    J Infect Dis. 2021;224:989-994.
    >> Share

  153. PROBERT WS, Glenn-Finer R, Espinosa A, Yen C, et al
    Molecular Epidemiology of Measles in California, United States-2019.
    J Infect Dis. 2021;224:1015-1023.
    >> Share

  154. GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
    Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
    J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
    >> Share

  155. SAHA SK, Tabassum N, Saha S
    Typhoid Conjugate Vaccine - an urgent tool to combat typhoid, and tackle antimicrobial resistance.
    J Infect Dis. 2021 Sep 16. pii: 6371004. doi: 10.1093.
    >> Share

  156. ZAMAN K, Aziz AB, Yunus M, Qadri F, et al
    Rotavirus vaccine trials in icddr,b and future use of the vaccine in Bangladesh.
    J Infect Dis. 2021 Sep 16. pii: 6371003. doi: 10.1093.
    >> Share

  157. BIRKHOLD M, Mwisongo A, Pollard AJ, Neuzil KM, et al
    Typhoid conjugate vaccine in Africa and Asia: Status of clinical evaluation and vaccine introduction.
    J Infect Dis. 2021 Sep 16. pii: 6370981. doi: 10.1093.
    >> Share

  158. ZEEVAT F, Luttjeboer J, Paulissen JHJ, van der Schans J, et al
    Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom.
    J Infect Dis. 2021 Sep 15. pii: 6370470. doi: 10.1093.
    >> Share

  159. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    >> Share

  160. MATTHIAS KA, Connolly KL, Begum AA, Jerse AE, et al
    Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.
    J Infect Dis. 2021 Sep 8. pii: 6366578. doi: 10.1093.
    >> Share

  161. KIM SS, Chung JR, Belongia EA, McLean HQ, et al
    mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
    J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
    >> Share

  162. MCMILLAN M, Koehler AP, Lawrence A, Sullivan TR, et al
    'B Part of It' School Leaver study: a repeat cross-sectional study to assess the impact of increasing coverage with meningococcal B (4CMenB) vaccine on carriage of Neisseria meningitidis.
    J Infect Dis. 2021 Sep 6. pii: 6364883. doi: 10.1093.
    >> Share

  163. RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
    Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
    J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
    >> Share

  164. PECK ME, Hampton LM, Antoni S, Ogbuanu I, et al
    Global Rotavirus and Pneumococcal Conjugate Vaccine Introductions and the Association With Country Disease Surveillance, 2006-2018.
    J Infect Dis. 2021;224.
    >> Share

  165. AHMED SS, Lessa FC, Coradin H, Sanchez J, et al
    High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
    J Infect Dis. 2021;224.
    >> Share

  166. FRANCOIS WATKINS LK, Milucky JL, McGee L, Sine St-Surin F, et al
    Nasopharyngeal Carriage of Streptococcus pneumoniae Among Young Children in Haiti Before Pneumococcal Conjugate Vaccine Introduction.
    J Infect Dis. 2021;224.
    >> Share

  167. KWAMBANA-ADAMS BA, Cohen AL, Hampton L, Nhantumbo AA, et al
    Toward Establishing Integrated, Comprehensive, and Sustainable Meningitis Surveillance in Africa to Better Inform Vaccination Strategies.
    J Infect Dis. 2021;224.
    >> Share

  168. RABOBA JL, Rahajamanana VL, Andriatahirintsoa EPR, Razafindrakoto AC, et al
    Decline in Vaccine-Type Streptococcus pneumoniae Serotypes Following Pneumococcal Conjugate Vaccine Introduction in Madagascar.
    J Infect Dis. 2021;224.
    >> Share

  169. NAKAMURA T, Cohen AL, Schwartz S, Mwenda JM, et al
    The Global Landscape of Pediatric Bacterial Meningitis Data Reported to the World Health Organization-Coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014-2019.
    J Infect Dis. 2021;224.
    >> Share

  170. SHRESTHA S, Stockdale LK, Gautam MC, Gurung M, et al
    Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.
    J Infect Dis. 2021;224.
    >> Share

  171. YAMBA K, Mpabalwani E, Nakazwe R, Mulendele E, et al
    The Burden of Invasive Bacterial Disease and the Impact of 10-Valent Pneumococcal Conjugate Vaccine in Children <5 years hospitalized for Meningitis in Lusaka, Zambia, 2010-2019.
    J Infect Dis. 2021;224.
    >> Share

  172. KABORE L, Adebanjo T, Njanpop-Lafourcade BM, Ouangraoua S, et al
    Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys.
    J Infect Dis. 2021;224.
    >> Share

  173. DUNN MG, Lessa FC, Sanchez J, Cordero R, et al
    Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic.
    J Infect Dis. 2021;224.
    >> Share

  174. SAHA S, Saha SK
    Invasive Bacterial Vaccine-Preventable Disease Surveillance: Successes and Lessons Learned in Bangladesh for a Sustainable Path Forward.
    J Infect Dis. 2021;224.
    >> Share

  175. DU PLESSIS M, de Gouveia L, Freitas C, Abera NA, et al
    The Role of Molecular Testing in Pediatric Meningitis Surveillance in Southern and East African Countries, 2008-2017.
    J Infect Dis. 2021;224.
    >> Share

    August 2021
  176. HOLMGREN J
    Modern History of Cholera Vaccines and the Pivotal Role of icddr,b.
    J Infect Dis. 2021 Aug 28. pii: 6359024. doi: 10.1093.
    >> Share

  177. GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
    Sex Differences in Influenza: The Challenge Study Experience.
    J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
    >> Share

  178. LINNIK J, Syedbasha M, Kaltenbach HM, Vogt D, et al
    Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant (HSCT) patients.
    J Infect Dis. 2021 Aug 20. pii: 6355382. doi: 10.1093.
    >> Share

  179. DE MIGUEL BUCKLEY R, Diaz-Menendez M, Garcia-Rodriguez J, Arribas JR, et al
    Seasonal coronavirus pneumonia after SARS-Cov-2 infection and vaccine: new frenemies?
    J Infect Dis. 2021 Aug 20. pii: 6355378. doi: 10.1093.
    >> Share

  180. NATHAN N, Prevost B, Lambert S, Schnuriger A, et al
    SARS-CoV-2 variant Delta infects all 6 siblings but spares Comirnaty (BNT162b2, BioNTech/Pfizer)-vaccinated parents.
    J Infect Dis. 2021 Aug 19. pii: 6354728. doi: 10.1093.
    >> Share

  181. YANG CY, Lee YY, Wei JC
    Interpreting prevention of COVID-19 and vaccines.
    J Infect Dis. 2021 Aug 18. pii: 6354219. doi: 10.1093.
    >> Share

  182. CONNOLLY KL, Pilligua-Lucas M, Gomez C, Costenoble-Caherty AC, et al
    Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection.
    J Infect Dis. 2021;224.
    >> Share

  183. SHAKYA M, Neuzil KM, Pollard AJ
    Prospects of future typhoid and paratyphoid vaccines in endemic countries.
    J Infect Dis. 2021 Aug 10. pii: 6347515. doi: 10.1093.
    >> Share

  184. BURKE RM, Tate JE, Parashar UD
    Global Experience with Rotavirus Vaccines.
    J Infect Dis. 2021 Aug 10. pii: 6347290. doi: 10.1093.
    >> Share

  185. SARKER P, Mily A, Ara A, Haque F, et al
    Functional antibodies and innate immune responses to WRSS1, a live oral Shigella sonnei vaccine candidate in Bangladeshi adults and children.
    J Infect Dis. 2021 Aug 10. pii: 6347306. doi: 10.1093.
    >> Share

  186. CHANG KC, Chang MH, Chen HL, Wu JF, et al
    Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV.
    J Infect Dis. 2021 Aug 7. pii: 6345224. doi: 10.1093.
    >> Share

  187. MAN I, Vanska S, Lehtinen M, Bogaards JA, et al
    Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
    J Infect Dis. 2021;224:481-491.
    >> Share

    July 2021
  188. EIDEN J, Volckaert B, Rudenko O, Aitchison R, et al
    Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain.
    J Infect Dis. 2021 Jul 29. pii: 6330582. doi: 10.1093.
    >> Share

  189. WINER RL, Lin J, Querec TD, Unger ER, et al
    Effectiveness Of Human Papillomavirus (HPV) Vaccination Against Penile Hpv Infection In Men Who Have Sex With Men And Transgender Women.
    J Infect Dis. 2021 Jul 28. pii: 6329629. doi: 10.1093.
    >> Share

  190. DEEN J, Clemens JD
    Assessment of vaccine herd protection: Lessons learned from cholera and typhoid vaccine trials.
    J Infect Dis. 2021 Jul 17. pii: 6323356. doi: 10.1093.
    >> Share

  191. PETRIE JG, Bazzi LA, McDermott AB, Follmann D, et al
    Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
    J Infect Dis. 2021;224:49-59.
    >> Share

  192. GIACOMELLI CAO R, Christian L, Xu Z, Jaramillo L, et al
    Early changes in interferon gene expression and antibody responses following influenza vaccination in pregnant women.
    J Infect Dis. 2021 Jul 1. pii: 6312681. doi: 10.1093.
    >> Share

    June 2021
  193. HUANG Y, Williamson BD, Moodie Z, Carpp LN, et al
    Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
    J Infect Dis. 2021 Jun 26. pii: 6310132. doi: 10.1093.
    >> Share

  194. VAHLE K, Gargano JW, Lewis RM, Querec TD, et al
    Prevalence of human papillomavirus among females older than recommended age for vaccination by birth cohort, United States 20032016.
    J Infect Dis. 2021 Jun 23. pii: 6308446. doi: 10.1093.
    >> Share

  195. SCHWARZ TF, Johnson C, Grigat C, Apter D, et al
    Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in non-pregnant women.
    J Infect Dis. 2021 Jun 19. pii: 6306104. doi: 10.1093.
    >> Share

  196. MESSINA NL, Pittet LF, Gardiner K, Freyne B, et al
    Neonatal BCG vaccination and infections in the first year of life: the MIS BAIR randomised controlled trial.
    J Infect Dis. 2021 Jun 19. pii: 6306399. doi: 10.1093.
    >> Share

  197. MA Y, Liu F, Lin T, Chen L, et al
    Large-scale identification of T cell epitopes derived from SARS-CoV-2 for the development of peptide vaccines against COVID-19.
    J Infect Dis. 2021 Jun 18. pii: 6305142. doi: 10.1093.
    >> Share

  198. BRINKMAN ID, Butler AL, de Wit J, van Binnendijk RS, et al
    Measles vaccination elicits a polyfunctional antibody response, which decays more rapidly in early vaccinated children.
    J Infect Dis. 2021 Jun 16. pii: 6301139. doi: 10.1093.
    >> Share

  199. DEMONBREUN AR, Sancilio A, Velez ME, Ryan DT, et al
    COVID-19 mRNA vaccination generates greater IgG levels in women compared to men.
    J Infect Dis. 2021 Jun 12. pii: 6297423. doi: 10.1093.
    >> Share

  200. WHITEHOUSE ER, Bonwitt J, Hughes CM, Lushima RS, et al
    Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015.
    J Infect Dis. 2021;223:1870-1878.
    >> Share

    May 2021
  201. MAHON BE, Simon J, Widdowson MA, Samai M, et al
    Baseline Asymptomatic Malaria Infection and Immunogenicity of rVSVDeltaG-ZEBOV-GP Vaccine: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2021 May 20. pii: 6278485. doi: 10.1093.
    >> Share

  202. FELDSTEIN LR, Ferdinands JM, Self WH, Randolph AG, et al
    Modeling the impacts of clinical influenza testing on influenza vaccine effectiveness estimates.
    J Infect Dis. 2021 May 20. pii: 6278475. doi: 10.1093.
    >> Share

  203. JOFFE S, Babiker A, Ellenberg SS, Fix A, et al
    Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials.
    J Infect Dis. 2021 May 19. pii: 6278127. doi: 10.1093.
    >> Share

  204. BIANCHI FP, Germinario CA, Migliore G, Vimercati L, et al
    BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report.
    J Infect Dis. 2021 May 19. pii: 6278131. doi: 10.1093.
    >> Share

  205. COREY L
    Behind the Scenes Heroes: the COVID-19 Vaccine Data and Safety Monitoring Board.
    J Infect Dis. 2021 May 19. pii: 6278073. doi: 10.1093.
    >> Share

  206. HOES J, King AJ, Schurink-van 't Klooster TM, Berkhof PJ, et al
    Vaccine effectiveness following routine immunization with bivalent HPV vaccine: Protection against incident genital HPV infections from a reduced-dosing schedule.
    J Infect Dis. 2021 May 8. pii: 6272563. doi: 10.1093.
    >> Share

  207. BURGOMASTER KE, Foreman BM, Aleshnick MA, Larman BC, et al
    Limited flavivirus cross-reactive antibody responses elicited by a ZIKV DNA vaccine candidate in humans.
    J Infect Dis. 2021 May 7. pii: 6271521. doi: 10.1093.
    >> Share

  208. BARTSCH SM, Wedlock PT, O'Shea KJ, Cox SN, et al
    Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination.
    J Infect Dis. 2021 May 6. pii: 6267841. doi: 10.1093.
    >> Share

    April 2021
  209. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    >> Share

  210. FERNANDEZ J, Sanders H, Henn J, Wilson JM, et al
    Vaccination with Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model.
    J Infect Dis. 2021 Apr 25. pii: 6251738. doi: 10.1093.
    >> Share

  211. SCHALTZ-BUCHHOLZER F, Aaby P, Monteiro I, Camala L, et al
    Immediate Bacille Calmette-Guerin vaccination to neonates requiring perinatal treatment at the maternity ward in Guinea-Bissau: A randomized controlled trial.
    J Infect Dis. 2021 Apr 24. pii: 6249562. doi: 10.1093.
    >> Share

  212. WILHELM M, Kaur A, Wernli M, Hirsch HH, et al
    BK Polyomavirus-Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination.
    J Infect Dis. 2021;223:1410-1422.
    >> Share

  213. KALKOWSKA DA, Pallansch MA, Cochi SL, Thompson KM, et al
    Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options.
    J Infect Dis. 2021 Apr 22. pii: 6246102. doi: 10.1093.
    >> Share

  214. SPINOLA SM, Zimet GD, Ott MA, Katz BP, et al
    Corrigendum to: Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure due to Ethical and Practical Issues.
    J Infect Dis. 2021 Apr 19. pii: 6226582. doi: 10.1093.
    >> Share

  215. EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
    Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
    J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
    >> Share

  216. BLUMENFELD O, Hampe CS, Shulman LM, Chen R, et al
    An Attenuation in the Incidence of Early Childhood Diabetes Correlates With Introduction of Rotavirus Vaccination in Israel.
    J Infect Dis. 2021;223:1305-1307.
    >> Share

  217. SALEEM AF, Mach O, Yousafzai MT, Kazi Z, et al
    One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.
    J Infect Dis. 2021;223:1214-1221.
    >> Share

  218. BEALL B, Walker H, Tran T, Li Z, et al
    Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.
    J Infect Dis. 2021;223:1241-1249.
    >> Share

  219. RAMAN R, Brennan J, Ndi D, Sloan C, et al
    Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines.
    J Infect Dis. 2021;223:1250-1259.
    >> Share

  220. WAGSTAFFE HR, Clutterbuck EA, Bockstal V, Stoop JN, et al
    Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
    J Infect Dis. 2021;223:1171-1182.
    >> Share

  221. ESONA MD, Ward ML, Wikswo ME, Rustempasic SM, et al
    Rotavirus Genotype Trends and Gastrointestinal Pathogen Detection in the United States, 2014-16: Results from the New Vaccine Surveillance Network.
    J Infect Dis. 2021 Apr 2. pii: 6209394. doi: 10.1093.
    >> Share

    March 2021
  222. JORDAN E, Lawrence SJ, Meyer TPH, Schmidt D, et al
    Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
    J Infect Dis. 2021;223:1062-1072.
    >> Share

  223. WANG K, Dropulic L, Bozekowski J, Pietz HL, et al
    Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus (HSV) Seronegative Recipients of the HSV529 Vaccine.
    J Infect Dis. 2021 Mar 15. pii: 6170962. doi: 10.1093.
    >> Share

  224. LEWNARD JA, Bruxvoort KJ, Fischer H, Hong VX, et al
    Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract.
    J Infect Dis. 2021 Mar 9. pii: 6164926. doi: 10.1093.
    >> Share

  225. FREY SE, Stapleton JT, Ballas ZK, Rasmussen WL, et al
    Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses.
    J Infect Dis. 2021 Mar 1. pii: 6155758. doi: 10.1093.
    >> Share

    February 2021
  226. WU HW, Park S, Pond-Tor S, Stuart R, et al
    Whole-proteome differential screening identifies novel vaccine candidates for schistosomiasis japonica.
    J Infect Dis. 2021 Feb 19. pii: 6133347. doi: 10.1093.
    >> Share

  227. KASEKE C, Tano-Menka R, Senjobe F, Gaiha GD, et al
    The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts.
    J Infect Dis. 2021;223.
    >> Share

  228. BEHR MA, Divangahi M, Schurr E
    Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.
    J Infect Dis. 2021;223:189-191.
    >> Share

  229. TSUJI I, Dominguez D, Egan MA, Dean HJ, et al
    Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine.
    J Infect Dis. 2021 Feb 3. pii: 6127289. doi: 10.1093.
    >> Share

  230. ENDY TP, Wang D, Polhemus ME, Jarman RG, et al
    A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain.
    J Infect Dis. 2021;223:258-267.
    >> Share

    January 2021
  231. DE PIJPER CA, Langedijk AC, Terryn S, Van Gucht S, et al
    Long-term memory response after a single intramuscular rabies booster vaccination, 10-24 years after primary immunization.
    J Infect Dis. 2021 Jan 27. pii: 6121364. doi: 10.1093.
    >> Share

  232. KURUP D, Fisher CR, Scher G, Yankowski C, et al
    Tetravalent rabies-vectored Filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates.
    J Infect Dis. 2021 Jan 9. pii: 6075344. doi: 10.1093.
    >> Share

  233. FAN X, Li N, Xu M, Yang D, et al
    Intrapulmonary Vaccination Induces Long-lasting and Effective Pulmonary Immunity against Staphylococcus aureus Pneumonia.
    J Infect Dis. 2021 Jan 8. pii: 6071502. doi: 10.1093.
    >> Share

    December 2020
  234. TENFORDE MW, Talbot HK, Trabue CH, Gaglani M, et al
    Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020.
    J Infect Dis. 2020 Dec 30. pii: 6055595. doi: 10.1093.
    >> Share

  235. BRICKLEY EB, Connor RI, Wieland-Alter W, Weiner JA, et al
    Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium.
    J Infect Dis. 2020 Dec 24. pii: 6046404. doi: 10.1093.
    >> Share

  236. KUBALE J, Balmaseda A, Sanchez N, Lopez R, et al
    Pneumonia following symptomatic influenza infection among Nicaraguan children before and after introduction of the pneumococcal conjugate vaccine.
    J Infect Dis. 2020 Dec 22. pii: 6044070. doi: 10.1093.
    >> Share

  237. CAPEDING MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, et al
    Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study.
    J Infect Dis. 2020 Dec 22. pii: 6044221. doi: 10.1093.
    >> Share

  238. KIMBALL J, Zhu Y, Wyatt D, Trabue CH, et al
    Influenza Vaccine Failure Associated with Age and Immunosuppression.
    J Infect Dis. 2020 Dec 19. pii: 6041867. doi: 10.1093.
    >> Share

  239. FERDINANDS JM, Gaglani M, Ghamande S, Martin ET, et al
    Vaccine effectiveness against influenza-associated hospitalizations among adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network.
    J Infect Dis. 2020 Dec 18. pii: 6041424. doi: 10.1093.
    >> Share

  240. SIERRA MS, Tsang SH, Hu S, Porras C, et al
    Risk Factors for NON-HPV16/18 Cervical Infections and Associated Lesions Among HPV-DNA-Negative Women Vaccinated Against HPV16/18 in the Costa Rica Vaccine Trial (CVT).
    J Infect Dis. 2020 Dec 16. pii: 6039229. doi: 10.1093.
    >> Share

  241. LOPEZ-MEDINA E, Biswal S, Saez-Llorens X, Borja-Tabora C, et al
    Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination.
    J Infect Dis. 2020 Dec 15. pii: 6034203. doi: 10.1093.
    >> Share

    November 2020
  242. BEHR MA, Divangahi M, Schurr E
    Lessons from BCG for SARS-CoV-2 vaccine candidates.
    J Infect Dis. 2020 Nov 30. pii: 6012502. doi: 10.1093.
    >> Share

  243. CLEMENS EA, Holbrook BC, Kanekiyo M, Yewdell JW, et al
    An R848 conjugated influenza virus vaccine elicits robust IgG to hemagglutinin stem in a newborn nonhuman primate model.
    J Infect Dis. 2020 Nov 27. pii: 6007684. doi: 10.1093.
    >> Share

  244. TAGBO BN, Verma H, Mahmud ZM, Ernest K, et al
    Randomized Controlled Clinical Trial of bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children.
    J Infect Dis. 2020 Nov 24. pii: 5999481. doi: 10.1093.
    >> Share

  245. CHLIBEK R, Bayas JM, Collins H, de la Pinta MLR, et al
    Erratum to: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >/=50 Years of Age.
    J Infect Dis. 2020 Nov 20. pii: 5993994. doi: 10.1093.
    >> Share

  246. PAYNE DC, McNeal M, Staat MA, Piasecki AM, et al
    Maternal Anti-Rotavirus IgG Antibodies Persist in the Post-Rotavirus Vaccine Era.
    J Infect Dis. 2020 Nov 19. pii: 5992213. doi: 10.1093.
    >> Share

  247. LAAKE I, Feiring B, Jonassen CM, Pettersson JH, et al
    Concurrent infection with multiple human papillomavirus types among unvaccinated and vaccinated 17-year-old Norwegian girls.
    J Infect Dis. 2020 Nov 17. pii: 5986714. doi: 10.1093.
    >> Share

  248. DE DEUS N, Capitine IPU, Bauhofer AFL, Marques S, et al
    Immunogenicity of reduced-dose monovalent type 2 oral poliovirus vaccine in Mocuba, Mozambique.
    J Infect Dis. 2020 Nov 12. pii: 5979486. doi: 10.1093.
    >> Share

  249. MARTIN ET, Cheng C, Petrie JG, Alyanak E, et al
    Low influenza vaccine effectiveness against A(H3N2) associated hospitalizations in the 2016-2017 and 2017-2018 seasons of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
    J Infect Dis. 2020 Nov 3. pii: 5952469. doi: 10.1093.
    >> Share

  250. SALMON DA, Dudley MZ, Carleton BC
    Guillain-Barre Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence.
    J Infect Dis. 2020 Nov 2. pii: 5952166. doi: 10.1093.
    >> Share

  251. PEREZ-VILAR S, Hu M, Weintraub E, Arya D, et al
    Guillain-Barre Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.
    J Infect Dis. 2020 Nov 2. pii: 5952165. doi: 10.1093.
    >> Share

    October 2020
  252. HANIFI SMA, Fisker AB, Welaga P, Rieckmann A, et al
    Diphtheria-tetanus-pertussis (DTP) vaccine is associated with increased female-male mortality rate ratios. A meta-analysis of studies of DTP administered before and after measles vaccine.
    J Infect Dis. 2020 Oct 30. pii: 5944053. doi: 10.1093.
    >> Share

  253. HINOJOSA M, Shepard SS, Chung JR, King JP, et al
    Impact of Immune Priming, Vaccination and Infection on Influenza A(H3N2) Antibody Landscapes in Children.
    J Infect Dis. 2020 Oct 22. pii: 5934948. doi: 10.1093.
    >> Share

  254. SHANNON I, White CL, Yang H, Nayak JL, et al
    Differences in influenza-specific CD4 T cell mediated immunity following acute infection versus inactivated vaccination in children.
    J Infect Dis. 2020 Oct 19. pii: 5930368. doi: 10.1093.
    >> Share

  255. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    >> Share

  256. MHANGO C, Mandolo JJ, Chinyama E, Wachepa R, et al
    Rotavirus Genotypes in Hospitalized Children with Acute Gastroenteritis Before and After Rotavirus Vaccine Introduction in Blantyre, Malawi, 1997 - 2019.
    J Infect Dis. 2020 Oct 9. pii: 5919783. doi: 10.1093.
    >> Share

  257. COX KS, Zhang L, Freed DC, Tang A, et al
    Functional Evaluation and Genetic Evolution of Human T-cell Responses after Vaccination with a Conditionally Replication-Defective Cytomegalovirus Vaccine.
    J Infect Dis. 2020 Oct 8. pii: 5919748. doi: 10.1093.
    >> Share

  258. MILLER M
    Establishing the Value and Strategies for Respiratory Syncytial Virus (RSV) Control: The European RSV Consortium (RESCEU).
    J Infect Dis. 2020;222.
    >> Share

  259. WILDENBEEST JG, Zuurbier RP, Korsten K, van Houten MA, et al
    Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
    J Infect Dis. 2020;222.
    >> Share

  260. CHUNG A, Reeves RM, Nair H, Campbell H, et al
    Hospital Admission Trends for Bronchiolitis in Scotland, 2001-2016: A National Retrospective Observational Study.
    J Infect Dis. 2020;222.
    >> Share

  261. KANN H, Lehtinen M, Eriksson T, Surcel HM, et al
    Sustained Cross-Reactive Antibody Responses After Human Papillomavirus Vaccinations: Up To 12 Years Follow-Up In The Finnish Maternity Cohort.
    J Infect Dis. 2020 Oct 3. pii: 5917504. doi: 10.1093.
    >> Share

  262. EYAL N, Lipsitch M, Smith PG
    Reply to Hasford and to Spinola et al.
    J Infect Dis. 2020;222:1574-1575.
    >> Share

    September 2020
  263. FRIEDMAN-KLABANOFF DJ, Travassos MA, Ifeonu OO, Agrawal S, et al
    Epitope-specific antibody responses to a Plasmodium falciparum subunit vaccine target in a malaria-endemic population.
    J Infect Dis. 2020 Sep 29. pii: 5913015. doi: 10.1093.
    >> Share

  264. LIN L, Koren MA, Paolino KM, Eckels KH, et al
    Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase I Randomized Clinical Trial.
    J Infect Dis. 2020 Sep 23. pii: 5910633. doi: 10.1093.
    >> Share

  265. TOTA JE, Struyf F, Hildesheim A, Gonzalez P, et al
    Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.
    J Infect Dis. 2020 Sep 5. pii: 5901687. doi: 10.1093.
    >> Share

  266. BURKE RM, Tate JE, Jiang B, Parashar UD, et al
    Rotavirus and Type 1 Diabetes-Is There a Connection? A Synthesis of the Evidence.
    J Infect Dis. 2020;222:1076-1083.
    >> Share

  267. PATEL MK, Antoni S, Nedelec Y, Sodha S, et al
    The Changing Global Epidemiology of Measles, 2013-2018.
    J Infect Dis. 2020;222:1117-1128.
    >> Share

    August 2020
  268. SADOFF J, De Paepe E, Haazen W, Omoruyi E, et al
    Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    J Infect Dis. 2020 Aug 26. pii: 5897745. doi: 10.1093.
    >> Share

  269. PANG Y, Wang Q, Lv M, Yu M, et al
    Influenza vaccination protects against hospitalization outcomes among older patients with cardiovascular or respiratory diseases.
    J Infect Dis. 2020 Aug 11. pii: 5890841. doi: 10.1093.
    >> Share

    July 2020
  270. CAMPBELL N, Verrall AJ, Donkor S, Sutherland JS, et al
    BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia.
    J Infect Dis. 2020 Jul 8. pii: 5868549. doi: 10.1093.
    >> Share

  271. EYAL N, Lipsitch M, Smith PG
    Response to Dawson et al.
    J Infect Dis. 2020;222:516-517.
    >> Share

  272. HU SY, Tsang SH, Chen F, Pan QJ, et al
    Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women.
    J Infect Dis. 2020 Jul 2. pii: 5866538. doi: 10.1093.
    >> Share

    June 2020
  273. EYAL N, Lipsitch M, Smith PG
    Response to Cioffi.
    J Infect Dis. 2020;222:169-170.
    >> Share

  274. NDEFFO-MBAH ML, Pandey A
    Global Risk and Elimination of Yellow Fever Epidemics.
    J Infect Dis. 2020;221:2026-2034.
    >> Share

    April 2020
  275. BOLOTIN S, Hughes SL, Gul N, Khan S, et al
    What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review.
    J Infect Dis. 2020;221:1576-1583.
    >> Share

  276. SCHWENDINGER M, Thiry G, De Vos B, Leroux-Roels G, et al
    A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
    J Infect Dis. 2020 Apr 21. pii: 5821369. doi: 10.1093.
    >> Share

  277. BURNETT E, Kabir F, Van Trang N, Rayamajhi A, et al
    Infectious Etiologies of Intussusception Among Children <2 Years Old in 4 Asian Countries.
    J Infect Dis. 2020;221:1499-1505.
    >> Share

    March 2020
  278. KURTOVIC L, Atre T, Feng G, Wines BD, et al
    Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial.
    J Infect Dis. 2020 Mar 31. pii: 5814271. doi: 10.1093.
    >> Share

  279. KAUSHAL D
    The Comeback Kid: BCG.
    J Infect Dis. 2020;221:1031-1032.
    >> Share

  280. HAIDAR G, Boeckh M, Singh N
    Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
    J Infect Dis. 2020;221.
    >> Share

  281. PLOTKIN SA
    Preventing Infection by Human Cytomegalovirus.
    J Infect Dis. 2020;221.
    >> Share

  282. NELSON CS, Baraniak I, Lilleri D, Reeves MB, et al
    Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.
    J Infect Dis. 2020;221.
    >> Share

  283. HALSTEAD SB, Russell PK, Brandt WE
    NS1, Dengue's Dagger.
    J Infect Dis. 2020;221:857-860.
    >> Share

    February 2020
  284. ATMAR RL, Ettayebi K, Ayyar BV, Neill FH, et al
    Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection.
    J Infect Dis. 2020;221:739-743.
    >> Share

  285. FAINGELERNT Y, Dagan R, Givon-Lavi N, Ben-Shimol S, et al
    Nasopharyngeal Carriage of Invasive Pneumococcal Serotypes During Childhood Community-Acquired Alveolar Pneumonia Is Associated With Specific Clinical Presentation.
    J Infect Dis. 2020;221:812-819.
    >> Share

  286. BAUTISTA-GOGEL J, Madsen CM, Lu X, Sakthivel SK, et al
    Outbreak of Respiratory Illness Associated With Human Adenovirus Type 7 Among Persons Attending Officer Candidates School, Quantico, Virginia, 2017.
    J Infect Dis. 2020;221:697-700.
    >> Share

  287. EISINGER RW, Embry AC, Read SW, Fauci AS, et al
    2019: A Banner Year for Tuberculosis Research.
    J Infect Dis. 2020 Feb 11. pii: 5719366. doi: 10.1093.
    >> Share

  288. ZIMMERMANN M, Hagedorn B, Lyons H
    Projection of Costs of Polio Eradication Compared to Permanent Control.
    J Infect Dis. 2020;221:561-565.
    >> Share

    January 2020
  289. MARAVELIA P, Frelin L, Ni Y, Perez NC, et al
    Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections.
    J Infect Dis. 2020 Jan 29. pii: 5717223. doi: 10.1093.
    >> Share

    December 2019
  290. THOMAS A, Hammarlund E, Gao L, Holman S, et al
    Loss of Pre-Existing Immunological Memory among HIV Infected Women Despite Immune Reconstitution with Antiretroviral Therapy.
    J Infect Dis. 2019 Dec 23. pii: 5684906. doi: 10.1093.
    >> Share

    November 2019
  291. UGARTE A, Romero Y, Tricas A, Casado C, et al
    Unintended HIV-1 Infection During Analytical Therapy Interruption.
    J Infect Dis. 2019 Nov 19. pii: 5631859. doi: 10.1093.
    >> Share

    October 2019
  292. COELHO-DOS-REIS JGA, Funakoshi R, Huang J, Pereira FV, et al
    Functional Human CD141+ Dendritic Cells in Human Immune System Mice.
    J Infect Dis. 2019 Oct 23. pii: 5606696. doi: 10.1093.
    >> Share

  293. KAO CM, Goymer J, Loh LN, Mahant A, et al
    Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies that Mediate Antibody Dependent Cellular Cytotoxicity in Protecting Neonates from Herpes Simplex Virus Type 1 and Type 2.
    J Infect Dis. 2019 Oct 10. pii: 5585046. doi: 10.1093.
    >> Share

  294. ROSS S, Pati P, Jensen TL, Goll JB, et al
    Cytomegalovirus genetic diversity following primary infection.
    J Infect Dis. 2019 Oct 8. pii: 5583881. doi: 10.1093.
    >> Share

    September 2019
  295. NAHM MH, Brissac T, Kilian M, Vlach J, et al
    Pneumococci Can Become Virulent by Acquiring a New Capsule From Oral Streptococci.
    J Infect Dis. 2019 Sep 7. pii: 5564845. doi: 10.1093.
    >> Share

    July 2019
  296. VERRALL AJ, Alisjahbana B, Apriani L, Novianty N, et al
    Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia.
    J Infect Dis. 2019 Jul 12. pii: 5531576. doi: 10.1093.
    >> Share

    March 2019
  297. DEY RJ, Dey B, Singh AK, Praharaj M, et al
    BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis.
    J Infect Dis. 2019 Mar 15. pii: 5381716. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016